Ataraxis Breast
The first clinically validated AI-native prognostic/predictive test for invasive breast cancer. Ataraxis Breast uses multi-modal patient data, including pathology slides from standard biopsy and surgery specimens, to predict patient outcomes and help personalize treatment decisions in all breast cancer subtypes.
Clinical Development & Validation
Robust development and validation data
Ataraxis Breast was developed and validated using data from 8,161 breast cancer patients treated at 15 institutions in 7 countries.
The study included patients with all subtypes of early-stage and locally advanced invasive breast cancer, marking this as one of the most comprehensive evaluations of a prognostic/predictive test.
50% larger error reduction compared to standard of care genomic tests
In validation of Ataraxis Breast on three external cohorts from top international cancer centers, Ataraxis Breast reduced prediction error by approximately 50% compared to the standard of care genomic assays for hormone receptor-positive invasive breast cancer.
Works in all clinically relevant invasive breast cancer subgroups
Ataraxis Breast was developed and validated on robust and diverse data from seven countries. The data included previously underserved groups, such as triple-negative breast cancer patients. Ataraxis Breast was shown to be consistently prognostic across groups with various age, race, molecular and histological subtype, and nodal status.
View a Sample Report
Explore our sample report and learn more about how predictions made by Ataraxis Breast can help in recurrence risk assessment and making more personalized decisions about treatment.
Improved Clinical Workflows
1-Day Turnaround
No Tissue Exhausted
EHR Integration
Clinical Use Cases
Refine
Risk of recurrence is typically evaluated by analyzing standard clinicopathological factors and genomic assays. These methods are often limited in many critical groups or classify patients as “intermediate-risk”. Ataraxis Breast clearly identifies high- and low-risk patients in all invasive breast cancer subtypes.
Pre-Screen
Ataraxis Breast can provide results within one business day of receiving the pathology slides, and it works with core needle biopsy specimens. It can quickly identify patients with very low- or high-risk, helping deliver appropriate treatment on time, and avoiding unnecessary genomic testing, preserving it for future molecular profiling.
Replace
In our 8,000-patient study, Ataraxis Breast was shown to be more accurate in predicting recurrence and death than standard-of-care genomic assays. Ataraxis Breast can be ordered without any additional laboratory work or procedures and delivers results within 24 hours of receiving pathology slides.
New Answers
Ataraxis Breast works in all patients with invasive breast cancer, including triple-negative breast cancer (TNBC). Our recent validation study also showed that the test predicts recurrence and survival in HR+ patients treated with either endocrine therapy (ET) alone (candidates for adjuvant chemotherapy) or ET+chemotherapy (candidates for CDK4/6 inhibitors). Finally, the test was predictive of late recurrence and might be helpful in making decisions about extended endocrine therapy.
Frequently Asked Questions
Ataraxis Breast is intended to help physicians assess the risk of breast cancer recurrence, death, and therapeutic benefit for patients diagnosed with invasive breast cancer.
Ataraxis Breast is currently available for Research Use Only. We are committed to providing patients access to Ataraxis Breast as soon as possible and regardless of their financial situation.
We deliver results within one business day of receiving slides.
Please Contact Us. Ataraxis Breast is currently available for Research Use Only and is expected to be available commercially soon.
No, Ataraxis Breast does not require any additional procedures as it uses existing biopsy or resection specimens.
Empowering physicians with advanced multi-modal tools to improve treatment selection and patient outcomes.